Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Blood

Retrieve available abstracts of 332 articles:
HTML format

Single Articles

    June 2022
  1. PAREKH A, Keller FG, McCarten KM, Kessel S, et al
    Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis.
    Blood. 2022 Jun 28. pii: 485708. doi: 10.1182/blood.2022016098.
    PubMed     Abstract available

  2. PINDZOLA GM, Razzaghi R, Tavory RN, Nguyen HT, et al
    Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.
    Blood. 2022 Jun 27. pii: 485703. doi: 10.1182/blood.2022015926.
    PubMed     Abstract available

  3. FERRERO S, Grimaldi D, Genuardi E, Drandi D, et al
    Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma.
    Blood. 2022 Jun 23. pii: 485688. doi: 10.1182/blood.2021014270.
    PubMed     Abstract available

    Smart salvage treatment for Hodgkin lymphoma.
    Blood. 2022;139:3563-3564.

  5. IZQUIERDO E, Vorholt D, Blakemore S, Sackey B, et al
    Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.
    Blood. 2022;139:3617-3629.
    PubMed     Abstract available

  6. BACKER K, Wang HY
    Florid reactive follicular hyperplasia with exuberant HHV8 infection.
    Blood. 2022;139:3558.

  7. KAMBHAMPATI S, Saumoy M, Schneider Y, Pak S, et al
    Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma.
    Blood. 2022 Jun 14. pii: 485545. doi: 10.1182/blood.2022016624.
    PubMed     Abstract available

  8. GHIONE P, Palomba ML, Patel A, Bobillo S, et al
    Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
    Blood. 2022 Jun 9. pii: 485518. doi: 10.1182/blood.2021014375.
    PubMed     Abstract available

  9. PETERSON JM, Lyapichev KA
    Extranodal natural killer/T-cell lymphoma of the palate.
    Blood. 2022;139:3450.

  10. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
    High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
    Blood. 2022;139:3303-3313.
    PubMed     Abstract available

    May 2022
  11. HAMNVAG HM, Velankar M
    Hemophagocytic lymphohistiocytosis with multiple possible etiologies including rare primary bone marrow lymphoma.
    Blood. 2022;139:3226.

  12. KAMDAR M
    A cauldron of choices.
    Blood. 2022;139:3103-3104.

    A (modifiable) way to better Hodgkin lymphoma survivorship?
    Blood. 2022;139:3004-3005.

  14. CALABRETTA E, Hamadani M, Carlo-Stella C
    Blood. 2022 May 17. pii: 485279. doi: 10.1182/blood.2021014663.
    PubMed     Abstract available

  15. ALI A, Goy A, Dunleavy K
    CAR T-cell Therapy in Highly-Aggressive B-Cell Lymphoma: Emerging Biological and Clinical Insights.
    Blood. 2022 May 13. pii: 485238. doi: 10.1182/blood.2022016226.
    PubMed     Abstract available

  16. ATANACKOVIC D, Luetkens T, Omili D, Iraguha T, et al
    Vaccine-induced T cells against Sars-Cov-2 and its Omicron variant in B cell-depleted lymphoma patients after CART.
    Blood. 2022 May 10. pii: 485211. doi: 10.1182/blood.2022016175.

  17. CHERNG HJ, Sun R, Sugg B, Irwin R, et al
    Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma.
    Blood. 2022 May 5. pii: 485178. doi: 10.1182/blood.2022015601.
    PubMed     Abstract available

  18. NAKAMURA A, Grossman S, Song K, Xega K, et al
    The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
    Blood. 2022;139:2770-2781.
    PubMed     Abstract available

    April 2022
  19. TADROS S, Jaffe ES
    A novel case of gamma-delta T-cell lymphoma expressing CD4, recapitulating a stage of gamma-delta T-cell development.
    Blood. 2022;139:2725.

  20. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-3603.
    Blood. 2022;139:2726.

  21. SONIGO G, Bozonnat A, Dumont M, Thonnart N, et al
    Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome.
    Blood. 2022;139:2712-2716.

  22. JAIN MD, Ziccheddu B, Coughlin CA, Faramand RG, et al
    Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
    Blood. 2022 Apr 27. pii: 485092. doi: 10.1182/blood.2021015008.
    PubMed     Abstract available

    CNS prophylaxis in DLBCL: first do no harm.
    Blood. 2022;139:2420-2421.

  24. WILSON MR, Eyre TA, Kirkwood AA, Wong Doo N, et al
    Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
    Blood. 2022;139:2499-2511.
    PubMed     Abstract available

  25. BEYGI S, Duran GE, Fernandez-Pol S, Rook AH, et al
    Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.
    Blood. 2022 Apr 18. pii: 484969. doi: 10.1182/blood.2021014468.
    PubMed     Abstract available

  26. CHONG EA, Schuster SJ
    No CNS sanctuary for lymphoma from CAR T.
    Blood. 2022;139:2261-2263.

    Chemotherapy-free regimens in frontline follicular lymphoma.
    Blood. 2022;139:2263-2264.

    Turning up the heat on salivary gland MALT lymphoma.
    Blood. 2022;139:2094-2096.

    March 2022
  29. LIANG HC, Elenitoba-Johnson KSJ
    Targeting IMiD-resistant T-cell lymphoma.
    Blood. 2022;139:1932-1933.

  30. WU W, Nelson GM, Koch R, Donovan KA, et al
    Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
    Blood. 2022;139:2024-2037.
    PubMed     Abstract available

  31. QI Y, Zhao M, Hu Y, Wang Y, et al
    Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Blood. 2022 Mar 25. pii: 484499. doi: 10.1182/blood.2021013733.
    PubMed     Abstract available

  32. KURTZ DM
    The many facets of liquid biopsies in lymphoma.
    Blood. 2022;139:1780-1781.

  33. DE MASSON A, Darbord D, Dobos G, Boisson M, et al
    Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
    Blood. 2022;139:1820-1832.
    PubMed     Abstract available

  34. SIDDIQI T, Soumerai JD, Dorritie KA, Stephens DM, et al
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Blood. 2022;139:1794-1806.
    PubMed     Abstract available

  35. MEI MG, Lee HJ, Palmer J, Chen RW, et al
    Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE).
    Blood. 2022 Mar 22. pii: 484451. doi: 10.1182/blood.2022015423.
    PubMed     Abstract available

  36. BETHGE WA, Martus P, Schmitt M, Holtick U, et al
    GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany.
    Blood. 2022 Mar 22. pii: 484450. doi: 10.1182/blood.2021015209.
    PubMed     Abstract available

  37. SONG Y, Zhou K, Zou DH, Zhou J, et al
    Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
    Blood. 2022 Mar 18. pii: 484435. doi: 10.1182/blood.2021014162.
    PubMed     Abstract available

    POD24 in follicular lymphoma: time to be "wise".
    Blood. 2022;139:1609-1610.

  39. Bobillo S, Joffe E, Lavery JA, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021;137(1):39-48.
    Blood. 2022;139:1772.

  40. AYPAR U, Ewalt MD
    A very Burkitt-like case of Burkitt-like lymphoma with 11q aberration.
    Blood. 2022;139:1771.

  41. CASULO C, Dixon JG, Le-Rademacher J, Hoster E, et al
    Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Blood. 2022;139:1684-1693.
    PubMed     Abstract available

  42. PORPACZY E, Jager U
    How I manage autoimmune cytopenias in patients with lymphoid cancer.
    Blood. 2022;139:1479-1488.
    PubMed     Abstract available

  43. NAYAK L, Batchelor TT
    How I treat neurologic complications in patients with lymphoid cancer.
    Blood. 2022;139:1469-1478.
    PubMed     Abstract available

  44. WESTIN JR, Sehn L
    CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?
    Blood. 2022 Mar 3. pii: 484263. doi: 10.1182/blood.2022015789.
    PubMed     Abstract available

  45. LULLA PD
    CAR T cells and autologous transplantation can coexist for DLBCL.
    Blood. 2022;139:1266-1267.

  46. SHADMAN M, Pasquini M, Ahn KW, Chen Y, et al
    Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
    Blood. 2022;139:1330-1339.
    PubMed     Abstract available

    February 2022

  47. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
    Blood. 2022;139:1256.

  48. MARTIN P, Bartlett NL, Chavez JC, Reagan JL, et al
    Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
    Blood. 2022;139:1147-1159.
    PubMed     Abstract available

  49. SHAH NN, Harrington AM
    Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy.
    Blood. 2022;139:1116.

  50. CHONG EA, Alanio C, Svoboda J, Nasta SD, et al
    Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
    Blood. 2022;139:1026-1038.
    PubMed     Abstract available

  51. FRIGAULT MJ, Dietrich J, Gallagher KME, Roschewski MJ, et al
    Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial.
    Blood. 2022 Feb 15. pii: 484042. doi: 10.1182/blood.2021014738.
    PubMed     Abstract available

  52. KIM DH, Vega F
    Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
    Blood. 2022;139:951.

  53. CAO X, Wang Y, Zhang W, Zhong X, et al
    Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced suppression.
    Blood. 2022 Feb 8. pii: 483887. doi: 10.1182/blood.2021013901.
    PubMed     Abstract available

  54. DEAGLIO S, Vaisitti T
    A new taxonomy for splenic marginal zone lymphoma.
    Blood. 2022;139:644-645.

  55. YU YT, Chang KC
    Burkitt-like lymphoma with 11q aberrations: a highly apoptotic and high-grade lymphoma.
    Blood. 2022;139:797.

  56. DAVIDS MS, Rogers KA, Tyekucheva S, Wang Z, et al
    Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Blood. 2022;139:686-689.
    PubMed     Abstract available

    January 2022
  57. KLEIN U
    Metabolic path toward TCF3 inactivation in Burkitt lymphoma.
    Blood. 2022;139:475-476.

  58. TARIQ H, Zahra U
    Fibrin-associated diffuse large B-cell lymphoma with aberrant CD4 expression.
    Blood. 2022;139:635.

  59. WILKE AC, Doebele C, Zindel A, Lee KS, et al
    SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
    Blood. 2022;139:538-553.
    PubMed     Abstract available

  60. AARAKAKI H, Karube K
    Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.
    Blood. 2022;139:465.

  61. SCHMITZ N, Frontzek F
    CNS prophylaxis in DLBCL: time to say goodbye?
    Blood. 2022;139:315-317.

  62. ORELLANA-NOIA VM, Reed DR, McCook AA, Sen JM, et al
    Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
    Blood. 2022;139:413-423.
    PubMed     Abstract available

    PET imaging: back in the game for gastric EMZL?
    Blood. 2022;139:154-155.

  64. FUJIHARA M, Sakata R, Yoshida N, Ozasa K, et al
    Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.
    Blood. 2022;139:217-227.
    PubMed     Abstract available

  65. SHEN Y, Zhou J, Nie K, Cheng S, et al
    Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas.
    Blood. 2022;139:73-86.
    PubMed     Abstract available

  66. ANDRADES DELGADO A, Alvarez-Perez JC, Patino-Mercau JR, Cuadros M, et al
    Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes.
    Blood. 2022 Jan 5. pii: 483332. doi: 10.1182/blood.2021011708.

    December 2021
  67. MOSKOWITZ AJ, Ghione P, Jacobsen E, Ruan J, et al
    A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
    Blood. 2021;138:2828-2837.
    PubMed     Abstract available

  68. LIU H, Hu S
    EBV+ ALK+ large B-cell lymphoma.
    Blood. 2021;138:2741.

  69. BACHY E, Houot R, Feugier P, Bouabdallah K, et al
    Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy.
    Blood. 2021 Dec 22. pii: 483234. doi: 10.1182/blood.2021013526.
    PubMed     Abstract available

  70. HAWKES EA, Barraclough A, Sehn LH
    Limited-stage Diffuse Large B-cell Lymphoma.
    Blood. 2021 Dec 21. pii: 483215. doi: 10.1182/blood.2021013998.
    PubMed     Abstract available

  71. MERIRANTA L, Alkodsi A, Pasanen A, Lepisto M, et al
    Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Blood. 2021 Dec 21. pii: 483214. doi: 10.1182/blood.2021012852.
    PubMed     Abstract available

  72. JONAK C, Brunner PM
    Blood will tell: profiling Sezary syndrome.
    Blood. 2021;138:2450-2451.

    B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion.
    Blood. 2021;138:2593.

  74. NAJIDH S, Tensen CP, van der Sluijs-Gelling AJ, Teodosio C, et al
    Improved Sezary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sezary syndrome.
    Blood. 2021;138:2539-2554.
    PubMed     Abstract available

  75. TONC E, Takeuchi Y, Chou C, Xia Y, et al
    Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
    Blood. 2021;138:2526-2538.
    PubMed     Abstract available

  76. GABALLA MR, Banerjee PP, Milton DR, Jiang X, et al
    Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.
    Blood. 2021 Dec 16. pii: 483090. doi: 10.1182/blood.2021013290.
    PubMed     Abstract available

  77. BUUS TB, Koralov SB
    Oncogenic fusions JAK up CD8+ cytotoxic CTCL.
    Blood. 2021;138:2311-2312.

  78. LEE K, Evans MG, Yang L, Ng S, et al
    Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
    Blood. 2021;138:2435-2440.

  79. ALCANTARA M, Houillier C, Blonski M, Rubio MT, et al
    CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the clinical experience of the French LOC network.
    Blood. 2021 Dec 6. pii: 482903. doi: 10.1182/blood.2021012932.

  80. WILLIAMS AM, Mirzaei Salehabadi S, Xing M, Phillips NS, et al
    Modifiable Risk Factors for Neurocognitive and Psychosocial Problems After Hodgkin Lymphoma.
    Blood. 2021 Dec 3. pii: 482888. doi: 10.1182/blood.2021013167.
    PubMed     Abstract available

  81. WANG Z, Guo R, Trudeau SJ, Wolinsky E, et al
    CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival.
    Blood. 2021;138:2216-2230.
    PubMed     Abstract available

    November 2021
  82. ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
    PubMed     Abstract available

  83. YANG G, Wang J, Tan L, Munshi M, et al
    The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Blood. 2021;138:1966-1979.
    PubMed     Abstract available

  84. WARD J, Berrien-Elliott MM, Gomez F, Luo J, et al
    Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Blood. 2021 Nov 15. pii: 477971. doi: 10.1182/blood.2021011894.
    PubMed     Abstract available

  85. FANG H, Xu J
    Peripheral T-cell lymphoma with blastoid morphology and aberrant expression of multiple B-cell antigens.
    Blood. 2021;138:1906.

  86. ZHANG J, Lucas D
    A young microenvironment promotes B-ALL in mice.
    Blood. 2021;138:1789-1790.

  87. OLSEN EA, Whittaker S, Willemze R, Pinter-Brown L, et al
    Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
    Blood. 2021 Nov 10. pii: 477944. doi: 10.1182/blood.2021012057.
    PubMed     Abstract available

    October 2021
  88. OKWAN-DUODU D, Huang Q
    Primary splenic Burkitt-like lymphoma with 11q aberration.
    Blood. 2021;138:1642.

    Sugar-modified B-cell receptors in DLBCL.
    Blood. 2021;138:1512-1514.

  90. CHIODIN G, Allen JD, Bryant DJ, Rock P, et al
    Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.
    Blood. 2021;138:1570-1582.
    PubMed     Abstract available

  91. SCHAFF LR, Grommes C
    Primary Central Nervous System Lymphoma.
    Blood. 2021 Oct 26. pii: S0006-4971(21)01788-2. doi: 10.1182/blood.2020008377.
    PubMed     Abstract available

  92. KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
    Whole-genome landscape of adult T-cell leukemia/lymphoma.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
    PubMed     Abstract available

  93. EYRE TA, Cheah CY, Wang ML
    Therapeutic options for relapsed/refractory mantle cell lymphoma.
    Blood. 2021 Oct 22. pii: S0006-4971(21)01781-X. doi: 10.1182/blood.2021013326.
    PubMed     Abstract available

  94. WILSON MH, Gottschalk S
    Expect the unexpected: piggyBac and lymphoma.
    Blood. 2021;138:1379-1380.

  95. GROS A, Merlio JP
    Single-cell trajectories in Sezary syndrome.
    Blood. 2021;138:1384-1386.

  96. LIEBERS N, Speer C, Benning L, Bruch PM, et al
    Humoral and cellular responses after COVID-19 vaccination in anti-CD20 treated lymphoma patients.
    Blood. 2021 Oct 20. pii: 477393. doi: 10.1182/blood.2021013445.

  97. JOHNSTON RL, Mottok A, Chan FC, Jiang A, et al
    Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.
    Blood. 2021 Oct 18. pii: 477371. doi: 10.1182/blood.2021011941.
    PubMed     Abstract available

  98. KARACA ATABAY E, Mecca C, Wang Q, Ambrogio C, et al
    Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
    Blood. 2021 Oct 17. pii: 477348. doi: 10.1182/blood.2020008136.
    PubMed     Abstract available

  99. BONFIGLIO F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, et al
    Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma.
    Blood. 2021 Oct 15. pii: 477330. doi: 10.1182/blood.2021012386.
    PubMed     Abstract available

    PD-1 loss and T-cell exhaustion in CTCL tumoral T cells.
    Blood. 2021;138:1201-1203.

  101. PARK J, Daniels J, Wartewig T, Ringbloom KG, et al
    Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity.
    Blood. 2021;138:1225-1236.
    PubMed     Abstract available

    September 2021
  102. XU D, Naresh KN
    Leukemic presentation of a highly aggressive ALK-negative anaplastic large cell lymphoma.
    Blood. 2021;138:1198.

  103. STEPHENS DM, Byrd JC
    Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Blood. 2021;138:1099-1109.
    PubMed     Abstract available

  104. MINDERMAN M, Amir A, Kraan W, Schilder-Tol EJM, et al
    Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.
    Blood. 2021;138:1194-1197.

  105. LIU F, Gao Y, Xu B, Xiong S, et al
    PEG10 amplification at 7q21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma.
    Blood. 2021 Sep 28. pii: 477066. doi: 10.1182/blood.2021012091.
    PubMed     Abstract available

  106. TENSEN CP, Quint KD, Vermeer MH
    Genetic and epigenetic insights into cutaneous T-cell lymphoma.
    Blood. 2021 Sep 27. pii: 477053. doi: 10.1182/blood.2019004256.
    PubMed     Abstract available

    Cell cycle control in Richter transformation.
    Blood. 2021;138:1005-1007.

  108. GAO J, Sidiropoulou E, Walker I, Krupka JA, et al
    SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence.
    Blood. 2021;138:959-964.
    PubMed     Abstract available

  109. MAYERHOEFER M, Raderer M, Lamm W, Weber M, et al
    CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line H. pylori eradication.
    Blood. 2021 Sep 15. pii: 476918. doi: 10.1182/blood.2021013239.
    PubMed     Abstract available

  110. OLSZEWSKI A, Kurt H, Evens AM
    Defining and Treating High-grade B-cell lymphoma, NOS.
    Blood. 2021 Sep 15. pii: 476913. doi: 10.1182/blood.2020008374.
    PubMed     Abstract available

  111. DANIELS J, Choi J
    BACH2 is a putative T cell lymphoma tumor suppressor that may play a role in product-derived CAR-T cell lymphomas.
    Blood. 2021 Sep 9. pii: 476840. doi: 10.1182/blood.2021012641.

  112. SAVAGE KJ
    Primary mediastinal Large B-cell Lymphoma.
    Blood. 2021 Sep 9. pii: 476814. doi: 10.1182/blood.2020008376.
    PubMed     Abstract available

  113. GERMANS SK, Chen M
    Myeloid/lymphoid neoplasm with FGFR1 rearrangement.
    Blood. 2021;138:912.

  114. SCHMITT A, Xu W, Bucher P, Grimm M, et al
    Dimethyl fumarate induces ferroptosis and impairs NF-kappaB/STAT3 signaling in DLBCL.
    Blood. 2021;138:871-884.
    PubMed     Abstract available

  115. SCHMIDT RA, Lee AY
    How I treat and prevent venous thrombotic complications in patients with lymphoma.
    Blood. 2021 Sep 3. pii: 476786. doi: 10.1182/blood.2019003689.
    PubMed     Abstract available

  116. CARBONE A, Vaccher E, Gloghini A
    Hematological cancers in individuals infected by HIV.
    Blood. 2021 Sep 1. pii: 476746. doi: 10.1182/blood.2020005469.
    PubMed     Abstract available

    August 2021
    "Allo" from the (marginal) zone.
    Blood. 2021;138:595-596.

  118. HERLING M, Wahnschaffe L
    Altered epigenetics at the center of NK-LGL leukemia.
    Blood. 2021;138:589-591.

  119. CHOI Y, Diefenbach C
    Expanding landscape for relapsed Hodgkin lymphoma.
    Blood. 2021;138:421-422.

  120. GALINDO-CAMPOS MA, Lutfi N, Bonnin S, Martinez C, et al
    Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
    Blood. 2021 Aug 6. pii: 476527. doi: 10.1182/blood.2021012805.
    PubMed     Abstract available

    Epigenetic balance in DLBCL.
    Blood. 2021;138:355-356.

  122. HEWARD J, Konali L, D'Avola A, Close K, et al
    KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
    Blood. 2021;138:370-381.
    PubMed     Abstract available

    July 2021
  123. XU W, Berning P, Lenz G
    Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 28. pii: 476467. doi: 10.1182/blood.2020006784.
    PubMed     Abstract available

  124. ADVANI RH, Skrypets T, Civallero M, Spinner MA, et al
    Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
    Blood. 2021;138:213-220.
    PubMed     Abstract available

  125. DUNS G, Vigano E, Ennishi D, Sarkozy C, et al
    Characterization of DLBCL with a PMBL gene expression signature.
    Blood. 2021;138:136-148.
    PubMed     Abstract available

  126. TROTMAN J, Pettitt AR
    Is it time for PET-guided therapy in follicular lymphoma.
    Blood. 2021 Jul 14. pii: 476386. doi: 10.1182/blood.2020008243.
    PubMed     Abstract available

  127. HERRERA A, Cheng A, Mimitou EP, Seffens A, et al
    Multimodal single-cell analysis of cutaneous T cell lymphoma reveals distinct sub-clonal tissue-dependent signatures.
    Blood. 2021 Jul 7. pii: 476325. doi: 10.1182/blood.2020009346.
    PubMed     Abstract available

  128. ELUARD B, Nuan-Aliman S, Faumont N, Collares D, et al
    The alternative RelB NF-kappaB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 7. pii: 476326. doi: 10.1182/blood.2020010039.
    PubMed     Abstract available

  129. BURKE GAA
    Brentuximab vedotin: frontline help in ALCL.
    Blood. 2021;137:3581-3582.

  130. LOWE EJ, Reilly AF, Lim MS, Gross TG, et al
    Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Blood. 2021;137:3595-3603.
    PubMed     Abstract available

    June 2021
  131. BALSAS P, Veloza L, Clot G, Sureda-Gomez M, et al
    SOX11, CD70 and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma.
    Blood. 2021 Jun 29. pii: 476270. doi: 10.1182/blood.2020010527.
    PubMed     Abstract available

  132. GHIONE P, Gu JJ, Attwood K, Torka P, et al
    Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies.
    Blood. 2021 Jun 29. pii: 476275. doi: 10.1182/blood.2021012443.

  133. REJESKI K, Perez Perez A, Sesques P, Hoster E, et al
    CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
    Blood. 2021 Jun 24. pii: 476241. doi: 10.1182/blood.2020010543.
    PubMed     Abstract available

  134. MULLER MR
    A new option for Richter syndrome.
    Blood. 2021;137:3318-3319.

  135. PEYRON JF
    Blocking RiBi to suppress MYC lymphomagenesis.
    Blood. 2021;137:3316-3318.

    Mantle cell lymphoma continues to surprise, and inform!
    Blood. 2021;137:3158-3160.

  137. PASTORET C, Desmots F, Drillet G, Le Gallou S, et al
    Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
    Blood. 2021;137:3237-3250.
    PubMed     Abstract available

  138. KORONA B, Korona D, Zhao W, Wotherspoon A, et al
    GPR34 activation potentially bridges lymphoepithelial lesion to genesis of salivary gland MALT lymphoma.
    Blood. 2021 Jun 4. pii: 476070. doi: 10.1182/blood.2020010495.
    PubMed     Abstract available

  139. CAI J, Qing X
    Splenic marginal zone lymphoma with increased prolymphocytes.
    Blood. 2021;137:3150.

    May 2021
  140. MASS J, Park DC
    Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
    Blood. 2021;137:3002.

  141. PLAKS V, Rossi JM, Chou J, Wang L, et al
    CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
    Blood. 2021 May 27. pii: 476038. doi: 10.1182/blood.2021010930.
    PubMed     Abstract available

  142. SONG S, Cao C, Choukrallah MA, Tang F, et al
    OBF1 and Oct factors control the germinal center transcriptional program.
    Blood. 2021;137:2920-2934.
    PubMed     Abstract available

  143. BOIKO S, Proia T, San Martin M, Gregory GP, et al
    Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Blood. 2021;137:2947-2957.
    PubMed     Abstract available

  144. SOUSSAIN C, Malaise D, Cassoux N
    Primary vitreoretinal lymphoma: A diagnostic and management challenge.
    Blood. 2021 May 25. pii: 476013. doi: 10.1182/blood.2020008235.
    PubMed     Abstract available

  145. MAAS-BAUER K, Lohmeyer JK, Hirai T, Lopes Ramos T, et al
    Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects.
    Blood. 2021 May 25. pii: 476015. doi: 10.1182/blood.2021010887.
    PubMed     Abstract available

  146. REIMANN M, Schrezenmeier J, Richter-Pechanska P, Dolnik A, et al
    Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
    Blood. 2021;137:2785-2799.
    PubMed     Abstract available

  147. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    PubMed     Abstract available

    A new warhead in lymphoma therapy?
    Blood. 2021;137:2568-2570.

  149. VOSE JM
    Outcomes for PTCL: which pathway to success?
    Blood. 2021;137:2570-2571.

  150. SCHMITZ N, Truemper L, Bouabdallah K, Ziepert M, et al
    A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
    Blood. 2021;137:2646-2656.
    PubMed     Abstract available

  151. MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
    Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
    Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
    PubMed     Abstract available

  152. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    PubMed     Abstract available

  153. ZHAO Y, Wang E
    An effusion-based presentation of ALK- anaplastic large cell lymphoma.
    Blood. 2021;137:2563.

  154. MAMLOUK O, Nair R, Iyer SP, Edwards A, et al
    Safety of CAR T-cell therapy in kidney transplant recipients.
    Blood. 2021;137:2558-2562.

    April 2021
  155. DAVIES A
    DLBCL outcomes: much ventured, much GAINED.
    Blood. 2021;137:2277-2278.

  156. LE GOUILL S, Ghesquieres H, Oberic L, Morschhauser F, et al
    Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
    Blood. 2021;137:2307-2320.
    PubMed     Abstract available

  157. EPPERLA N, Herrera AF
    How we incorporate novel agents into the treatment of classic Hodgkin lymphoma.
    Blood. 2021 Apr 22. pii: 475828. doi: 10.1182/blood.2020007900.
    PubMed     Abstract available

  158. BLOMBERY P, Lade S
    Defining double-hit lymphoma in the clinic.
    Blood. 2021;137:2132-2133.

  159. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.

  160. FALCHI L, Ma H, Klein S, Lue JK, et al
    Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Blood. 2021;137:2161-2170.
    PubMed     Abstract available

  161. COLLINGE B, Ben-Neriah S, Chong L, Boyle M, et al
    The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.
    Blood. 2021;137:2196-2208.
    PubMed     Abstract available

  162. BALA TANNAN N, Manzari MT, Herviou L, Da Silva Ferreira M, et al
    Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
    Blood. 2021;137:2057-2069.
    PubMed     Abstract available

  163. SEWASTIANIK T, Straubhaar JR, Zhao JJ, Samur MK, et al
    miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
    Blood. 2021;137:1905-1919.
    PubMed     Abstract available

  164. ADVANI R, Moskowitz AJ, Bartlett NL, Vose J, et al
    Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
    Blood. 2021 Apr 7. pii: 475691. doi: 10.1182/blood.2020009178.
    PubMed     Abstract available

  165. Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.
    Blood. 2021;137:1844.

  166. CHIHARA D, Dores G, Flowers C, Morton LM, et al
    The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
    Blood. 2021 Apr 1. pii: 475679. doi: 10.1182/blood.2020010497.
    PubMed     Abstract available

  167. CAMPO E, Jaffe ES
    Taking gray zone lymphomas out of the shadows.
    Blood. 2021;137:1703-1704.

    March 2021
  168. ADVANI R, Skrypets T, Civallero M, Spinner MA, et al
    Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project.
    Blood. 2021 Mar 30. pii: 475653. doi: 10.1182/blood.2020010387.
    PubMed     Abstract available

  169. YU X, Li W, Deng Q, Liu H, et al
    MYD88 L265P elicits mutation-specific ubiquitination to drive NF-kappaB activation and lymphomagenesis.
    Blood. 2021;137:1615-1627.
    PubMed     Abstract available

  170. HAN H, Fan G, Song S, Jiang Y, et al
    piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.
    Blood. 2021;137:1603-1614.
    PubMed     Abstract available

  171. GUPTA M, Burns E, Georgantas NZ, Thierauf J, et al
    A Rapid Genotyping Panel for Detection of Primary Central Nervous System Lymphoma.
    Blood. 2021 Mar 18. pii: 475579. doi: 10.1182/blood.2020010137.
    PubMed     Abstract available

  172. Subsequent neoplasms in pediatric Hodgkin lymphoma.
    Blood. 2021;137:1562.

  173. PATRIARCA A, Gaidano G
    Intravascular lymphoma: from vessels to genes.
    Blood. 2021;137:1438-1439.

    Protect our children: Hodgkin lymphoma survivors.
    Blood. 2021;137:1433-1434.

  175. ROSCHEWSKI M, Phelan JD
    Sorting biologic subtypes of primary CNS lymphoma.
    Blood. 2021;137:1436-1437.

  176. HAEBE SE, Shree T, Sathe A, Day G, et al
    Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma.
    Blood. 2021 Mar 16. pii: 475531. doi: 10.1182/blood.2020009855.
    PubMed     Abstract available

  177. TIAN XP, Ma SY, Young KH, Ong CK, et al
    A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma.
    Blood. 2021 Mar 16. pii: 475529. doi: 10.1182/blood.2020010637.
    PubMed     Abstract available

    PD-1 blockade for untreated Hodgkin lymphoma.
    Blood. 2021;137:1271-1272.

  179. SHAH NN, Ahn KW, Litovich C, He Y, et al
    Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
    Blood. 2021;137:1416-1423.
    PubMed     Abstract available

  180. ELADL E, Chang H
    Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?
    Blood. 2021;137:1268.

  181. PIGNARRE A, Chatonnet F, Caron G, Haas M, et al
    Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction.
    Blood. 2021;137:1166-1180.
    PubMed     Abstract available

    February 2021
    CNS relapse in DLBCL: a calculable risk?
    Blood. 2021;137:1011-1012.

  183. TRUJILLO JA, Godfrey J, Hu Y, Huang J, et al
    Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
    Blood. 2021 Feb 24. pii: 475347. doi: 10.1182/blood.2020009148.

  184. DUMONTET E, Pangault C, Roulois D, Desoteux M, et al
    Extracellular vesicles shed by follicular lymphoma B cells promote the polarization of bone marrow stromal cell niche.
    Blood. 2021 Feb 24. pii: 475345. doi: 10.1182/blood.2020008791.
    PubMed     Abstract available

    Building on BTK inhibition in MCL.
    Blood. 2021;137:861-862.

  186. WIRTH A, Mikhaeel NG
    PET response-guided radiotherapy for advanced DLBCL?
    Blood. 2021;137:866-867.

  187. RULAND J
    Synergy of MALT1 and mTOR inhibition in DLBCL.
    Blood. 2021;137:724-725.

  188. MORSCHHAUSER F, Feugier P, Flinn IW, Gasiorowski R, et al
    A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
    Blood. 2021;137:600-609.
    PubMed     Abstract available

  189. VITOLO U, Novo M
    Bcl-2 inhibition in DLBCL: "the times they are a-changing"?
    Blood. 2021;137:577-579.

  190. CASULO C
    Checkpoint blockade in FL: eluding the king.
    Blood. 2021;137:581-582.

  191. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.

  192. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed     Abstract available

  193. DAHER M, Basar R, Gokdemir E, Baran N, et al
    Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
    Blood. 2021;137:624-636.
    PubMed     Abstract available

  194. STRATI P, Ahmed S, Furqan F, Fayad LE, et al
    Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma.
    Blood. 2021 Feb 3. pii: 475147. doi: 10.1182/blood.2020008865.
    PubMed     Abstract available

    January 2021
  195. THURNER L, Fadle N, Bittenbring JT, Regitz E, et al
    LRPAP1-autoantibodies in mantle cell lymphoma are associated with superior outcome.
    Blood. 2021 Jan 29. pii: 475090. doi: 10.1182/blood.2020008835.
    PubMed     Abstract available

  196. ABEYKOON JP, Wu X, Nowakowski KE, Dasari S, et al
    Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
    Blood. 2021;137:513-523.
    PubMed     Abstract available

  197. BOLEN CR, Mattiello F, Herold M, Hiddemann W, et al
    Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
    Blood. 2021 Jan 25. pii: 475041. doi: 10.1182/blood.2020008119.

    The balancing act in Burkitt lymphoma.
    Blood. 2021;137:289-291.

  199. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    PubMed     Abstract available

  200. JAIN MD, Zhao H, Wang X, Atkins R, et al
    Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma.
    Blood. 2021 Jan 15. pii: 474963. doi: 10.1182/blood.2020007445.
    PubMed     Abstract available

  201. MASS J, Alobeid B
    Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
    Blood. 2021;137:282.

  202. ISSA D, Seefat RL, Visser O, Zweegman S, et al
    Primary therapy and survival in patients with Burkitt lymphoma in the Netherlands: a population-based study, 1989-2018.
    Blood. 2021 Jan 14. pii: 474957. doi: 10.1182/blood.2020009552.

  203. DOMOSTEGUI A, Peddigari S, Mercer CA, Iannizzotto F, et al
    Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
    Blood. 2021 Jan 14. pii: 474958. doi: 10.1182/blood.2020007452.
    PubMed     Abstract available

  204. LOSSOS IS
    Stage I DLBCL: extranodal may mean extra radiation.
    Blood. 2021;137:3-5.

    December 2020
  205. KHANLARI M, Medeiros LJ
    ALK+ large B-cell lymphoma with aberrant expression of CD3.
    Blood. 2020;136:3086.

  206. SHIMADA K, Yoshida K, Suzuki Y, Iriyama C, et al
    Frequent Genetic Alterations in Immune Checkpoint-Related Genes in Intravascular Large B-Cell Lymphoma.
    Blood. 2020 Dec 24. pii: 474768. doi: 10.1182/blood.2020007245.
    PubMed     Abstract available

  207. FORBES LR
    Distract NK cell killing: give them a fatty meal.
    Blood. 2020;136:2969-2970.

  208. FUKUMOTO K, Sakata-Yanagimoto M, Fujisawa M, Sakamoto T, et al
    VAV1 mutations contribute to development of T-cell neoplasms in mice.
    Blood. 2020;136:3018-3032.
    PubMed     Abstract available

  209. BAIRD JH, Frank MJ, Craig J, Patel S, et al
    CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
    Blood. 2020 Dec 18. pii: 474751. doi: 10.1182/blood.2020009432.
    PubMed     Abstract available

  210. DE LEVAL L
    Chromosomes in breast lymphoma.
    Blood. 2020;136:2848-2849.

  211. LOS-DE VRIES GT, de Boer M, van Dijk E, Stathi P, et al
    Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma.
    Blood. 2020;136:2927-2932.
    PubMed     Abstract available

  212. YOUNES S, Natkunam Y
    Elusive sentinels at the Hodgkin checkpoint.
    Blood. 2020;136:2841-2842.

  213. GIULINO-ROTH L, Pei Q, Buxton A, Bush R, et al
    Subsequent malignant neoplasms among children with Hodgkin lymphoma: A report from the Children's Oncology Group.
    Blood. 2020 Dec 11. pii: 474601. doi: 10.1182/blood.2020007225.
    PubMed     Abstract available

  214. ELNAIR R, Lunning MA
    Checkpoint inhibition in ENKTL: Kno_le_ge G_ps.
    Blood. 2020;136:2721-2722.

  215. HAWKES EA
    Can PET eradicate irradiation in PMBCL?
    Blood. 2020;136:2725-2726.

  216. FOWLER N
    BCL-2 inhibition in follicular lymphoma: can we tip the scales?
    Blood. 2020;136:2598-2600.

    November 2020
  217. LIU H, Audino AN
    Metastatic nasopharyngeal carcinoma mimicking nodular sclerosis Hodgkin lymphoma.
    Blood. 2020;136:2596.

  218. ELLIN F, Savage KJ
    Is the CNS-PINK the new CNS risk model in ENKTL?
    Blood. 2020;136:2486-2487.

  219. HAMADANI M, Radford J, Carlo-Stella C, Caimi PF, et al
    Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Blood. 2020 Nov 19. pii: 474210. doi: 10.1182/blood.2020007512.
    PubMed     Abstract available

    Hodgkin lymphoma: outsmarting HRS cells.
    Blood. 2020;136:2362-2364.

  221. STEIDL C
    Architecture and interior design of Hodgkin lymphoma.
    Blood. 2020;136:2367-2369.

  222. YANG H, Green MR
    Harnessing lymphoma epigenetics to improve therapies.
    Blood. 2020 Nov 18. pii: 474151. doi: 10.1182/blood.2020006908.
    PubMed     Abstract available

  223. KLINTMAN J, Appleby N, Stamatopoulos B, Ridout K, et al
    Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
    Blood. 2020 Nov 18. pii: 474199. doi: 10.1182/blood.2020005650.
    PubMed     Abstract available

  224. GANDHI MK, Hoang T, Law SC, Brosda S, et al
    EBV-tissue positive primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
    Blood. 2020 Nov 17. pii: 474186. doi: 10.1182/blood.2020008520.
    PubMed     Abstract available

  225. LE GOUILL S, Morschhauser F, Chiron D, Bouabdallah K, et al
    Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial.
    Blood. 2020 Nov 12. pii: 474141. doi: 10.1182/blood.2020008727.
    PubMed     Abstract available

  226. VENTURUTTI L, Melnick AM
    The dangers of deja vu: memory B cells as the cells of origin of ABC-DLBCLs.
    Blood. 2020;136:2263-2274.
    PubMed     Abstract available

  227. GANG M, Marin ND, Wong P, Neal CC, et al
    CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
    Blood. 2020;136:2308-2318.
    PubMed     Abstract available

  228. CROMBIE JL, LaCasce AS
    The treatment of Burkitt lymphoma in adults.
    Blood. 2020 Nov 10. pii: 474125. doi: 10.1182/blood.2019004099.
    PubMed     Abstract available

  229. SPIEGEL JY, Dahiya S, Jain MD, Tamaresis JS, et al
    Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.
    Blood. 2020 Nov 6. pii: 474111. doi: 10.1182/blood.2020006245.

  230. KHANAM T, Sandmann S, Seggewiss J, Ruether CM, et al
    Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance.
    Blood. 2020 Nov 5. pii: 474099. doi: 10.1182/blood.2020005381.
    PubMed     Abstract available

  231. VERGE V, Soufan R
    COVID-19-induced atypical pulmonary lymphocytes.
    Blood. 2020;136:2241.

    October 2020
  232. REINKE S, Brockelmann PJ, Iaccarino I, Garcia-Marquez MA, et al
    Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
    Blood. 2020 Oct 28. pii: 469788. doi: 10.1182/blood.2020008553.
    PubMed     Abstract available

  233. COOK LB, Phillips AA
    How I treat Adult T-cell leukemia/lymphoma.
    Blood. 2020 Oct 19. pii: 469694. doi: 10.1182/blood.2019004045.
    PubMed     Abstract available

  234. FARHAT H, Ghanem H
    Primary cutaneous gammadelta T-cell lymphoma with secondary lung involvement.
    Blood. 2020;136:1892.

  235. HU G, Feldman AL
    Drivers of crizotinib resistance in ALK+ ALCL.
    Blood. 2020;136:1573-1575.

    NextGen CARs: the race is on.
    Blood. 2020;136:1570-1571.

    September 2020
  237. ALLEN PB, Savas H, Evens AM, Advani R, et al
    Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma.
    Blood. 2020 Sep 29. pii: 463993. doi: 10.1182/blood.2020007400.
    PubMed     Abstract available

  238. TWA DDW, Lee DG, Tan KL, Slack GW, et al
    Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma (DLBCL).
    Blood. 2020 Sep 23. pii: 463849. doi: 10.1182/blood.2020006338.

  239. SARKOZY C, Hung SS, Chavez EA, Duns G, et al
    Mutational Landscape of Grey Zone Lymphoma.
    Blood. 2020 Sep 22. pii: 463845. doi: 10.1182/blood.2020007507.
    PubMed     Abstract available

  240. MORSCHHAUSER F, Feugier P, Flinn IW, Gasiorowski R, et al
    A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
    Blood. 2020 Sep 21. pii: 463804. doi: 10.1182/blood.2020006578.
    PubMed     Abstract available

  241. SANDER B
    Under the cover of mantle cell lymphoma.
    Blood. 2020;136:1378-1379.

  242. STRATI P, Jain P, Johnson RJ, Forbes SG, et al
    Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma.
    Blood. 2020 Sep 15. pii: 463764. doi: 10.1182/blood.2020007994.

  243. ESTEVE-PUIG R, Climent F, Pineyro D, Domingo-Domenech E, et al
    Epigenetic Loss of m1A RNA Demethylase ALKBH3 in Hodgkin Lymphoma Targets Collagen Conferring Poor Clinical Outcome.
    Blood. 2020 Sep 11. pii: 463753. doi: 10.1182/blood.2020005823.

  244. WITZIG TE
    Myc matters in HIV-associated lymphoma.
    Blood. 2020;136:1217-1218.

  245. LOS-DE VRIES GT, De Boer M, van Dijk E, Stathi P, et al
    Chromosome 20 loss is characteristic for Breast implant-Associated Anaplastic Large Cell Lymphoma.
    Blood. 2020 Sep 8. pii: 463711. doi: 10.1182/blood.2020005372.
    PubMed     Abstract available

  246. RABOSO-GALLEGO J, Casado-Garcia A, Jiang X, Isidro-Hernandez M, et al
    Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.
    Blood. 2020 Sep 6. pii: 464123. doi: 10.1182/blood.2020004996.
    PubMed     Abstract available

  247. ORTUNO FJ, Amigo ML
    Triple-hit lymphoma with hyperbasophilic Burkitt-like morphology and solely bone marrow/leukemic phase presentation.
    Blood. 2020;136:1212.

  248. EICHENAUER DA, Engert A
    How I treat nodular lymphocyte-predominant Hodgkin Lymphoma.
    Blood. 2020 Sep 2. pii: 463607. doi: 10.1182/blood.2019004044.
    PubMed     Abstract available

  249. OLLILA TA, Kurt H, Waroich J, Vatkevich J, et al
    Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.
    Blood. 2020 Sep 2. pii: 463609. doi: 10.1182/blood.2020007236.

  250. FREEMAN CL, Savage KJ, Villa D, Scott DW, et al
    Long-Term Results of PET-Guided Radiation in Advanced-Stage Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
    Blood. 2020 Sep 1. pii: 463600. doi: 10.1182/blood.2020005846.
    PubMed     Abstract available

  251. GRIFFIN GK, Weirather JL, Roemer M, Lipschitz M, et al
    Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.
    Blood. 2020 Sep 1. pii: 463601. doi: 10.1182/blood.2020006464.
    PubMed     Abstract available

    August 2020
  252. ARMAND P, Janssens AM, Gritti G, Radford J, et al
    Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
    Blood. 2020 Aug 31. pii: 463592. doi: 10.1182/blood.2019004753.
    PubMed     Abstract available

  253. WANG HY, Tzachanis D
    Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
    Blood. 2020;136:1112.

  254. ZHANG Q, Casanova JL
    Human TET2 bridges cancer and immunity.
    Blood. 2020;136:1018-1019.

  255. Long-term limited-stage follicular lymphoma study.
    Blood. 2020;136:1013.

  256. KOBAYASHI T, Lam PY, Jiang H, Bednarska K, et al
    Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment.
    Blood. 2020 Aug 20. pii: 463339. doi: 10.1182/blood.2020005602.
    PubMed     Abstract available

  257. DUNLEAVY K, McLintock C
    How I Treat Lymphoma in Pregnancy.
    Blood. 2020 Aug 13. pii: 463256. doi: 10.1182/blood.2019000961.
    PubMed     Abstract available

  258. ZINZANI PL, Flinn IW, Yuen SLS, Topp MS, et al
    Venetoclax-rituximab +/- bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma: CONTRALTO.
    Blood. 2020 Aug 12. pii: 461787. doi: 10.1182/blood.2020005588.
    PubMed     Abstract available

  259. FONTAN GABAS L, Goldstein RL, Casalena G, Durant M, et al
    Identification of MALT1 Feedback Mechanisms Enables Rational Design of Potent Anti-Lymphoma Regimens for ABC-DLBCL.
    Blood. 2020 Aug 12. pii: 461786. doi: 10.1182/blood.2019004713.
    PubMed     Abstract available

  260. KIM SJ, Lim JQ, Laurensia Y, Cho J, et al
    Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
    Blood. 2020 Aug 7. pii: 461762. doi: 10.1182/blood.2020007247.
    PubMed     Abstract available

  261. GRANAI M, Lazzi S
    Early pattern of large B-cell lymphoma with IRF4 rearrangement.
    Blood. 2020;136:769.

    HOIP for targeting diffuse large B-cell lymphoma.
    Blood. 2020;136:646-647.

  263. JO T, Nishikori M, Kogure Y, Arima H, et al
    LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells.
    Blood. 2020;136:684-697.
    PubMed     Abstract available

  264. PRO B, Allen PB, Behdad A
    Hepatosplenic T-cell lymphoma: A rare but challenging entity.
    Blood. 2020 Aug 5. pii: 461707. doi: 10.1182/blood.2019004118.
    PubMed     Abstract available

    July 2020
  265. BARTLETT NL, Herrera AF, Domingo-Domenech E, Mehta A, et al
    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2020 Jul 30. pii: 461621. doi: 10.1182/blood.2019004701.
    PubMed     Abstract available

  266. BOBILLO S, Joffe E, Lavery JA, Sermer D, et al
    Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era.
    Blood. 2020 Jul 30. pii: 461623. doi: 10.1182/blood.2020005112.
    PubMed     Abstract available

  267. ALBERT MH, Hauck F
    EBV-triggered hemophagocytic lymphohistiocytosis in a boy with a history of non-Hodgkin lymphoma.
    Blood. 2020;136:644.

  268. WEIGERT O
    The different flavors and splices of MCL.
    Blood. 2020;136:526-527.

  269. EVENS AM, Danilov AV, Jagadeesh D, Sperling AL, et al
    Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers.
    Blood. 2020 Jul 14. pii: 461327. doi: 10.1182/blood.2020006926.
    PubMed     Abstract available

  270. Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129(24):3175-3183.
    Blood. 2020;136:259.

  271. FRIEDRICH C, Barreau S
    A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.
    Blood. 2020;136:148.

  272. LURAIN K, Uldrick TS, Ramaswami R, Polizzotto M, et al
    Treatment of HIV-associated Primary CNS Lymphoma with Antiretroviral Therapy, Rituximab, and High-Dose Methotrexate.
    Blood. 2020 Jul 1. pii: 461242. doi: 10.1182/blood.2020006048.

    June 2020
  273. HAYDEN A, Tonseth P, Lee DG, Villa D, et al
    Outcome of Primary Mediastinal Large B-cell Lymphoma Using R-CHOP: Impact of a PET Adapted Approach.
    Blood. 2020 Jun 30. pii: 461229. doi: 10.1182/blood.2019004296.
    PubMed     Abstract available

  274. VELDMAN J, Visser L, Huberts-Kregel M, Muller N, et al
    Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.
    Blood. 2020 Jun 26. pii: 461197. doi: 10.1182/blood.2020005546.
    PubMed     Abstract available

  275. LINDHOLM KE, Ewalt MD
    Hemophagocytic syndrome-associated intravascular large B-cell lymphoma.
    Blood. 2020;135:2432.

    NLP Hodgkin lymphoma: can we get away with less?
    Blood. 2020;135:2329-2330.

  277. NADEU F, Martin-Garcia D, Clot G, Diaz-Navarro A, et al
    Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes.
    Blood. 2020 Jun 25. pii: 461130. doi: 10.1182/blood.2020005289.
    PubMed     Abstract available

  278. KIM H, Jeong H, Yamaguchi M, Sohn I, et al
    Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
    Blood. 2020 Jun 25. pii: 461129. doi: 10.1182/blood.2020005026.
    PubMed     Abstract available

  279. PROKOPH N, Probst NA, Lee LC, Monahan JM, et al
    IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma.
    Blood. 2020 Jun 23. pii: 461097. doi: 10.1182/blood.2019003793.
    PubMed     Abstract available

  280. TONG C, Zhang Y, Liu Y, Ji X, et al
    Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma.
    Blood. 2020 Jun 18. pii: 461029. doi: 10.1182/blood.2020005278.
    PubMed     Abstract available

  281. MEIGNAN M, Gallamini A
    DeltaSUVmax for interim PET in DLBCL: old is new.
    Blood. 2020;135:2202-2203.

  282. ZHANG Q, Orlando E, Wang H, Bogusz AM, et al
    Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome.
    Blood. 2020 Jun 9. pii: 460737. doi: 10.1182/blood.2020005123.

  283. CHEN J, Goyal N, Dai L, Lin Z, et al
    Developing new ceramide analogs and identifying novel sphingolipid controlled genes against a virus-associated lymphoma.
    Blood. 2020 Jun 9. pii: 460736. doi: 10.1182/blood.2020005569.
    PubMed     Abstract available

  284. STREMENOVA SPEGAROVA J, Lawless D, Mohamad SMB, Engelhardt KR, et al
    Germline TET2 Loss-Of-Function Causes Childhood Immunodeficiency And Lymphoma.
    Blood. 2020 Jun 9. pii: 460739. doi: 10.1182/blood.2020005844.
    PubMed     Abstract available

  285. LINK BK
    Foreseeing what is to happen in DLBCL.
    Blood. 2020;135:2014-2015.

  286. BISHOP MR
    The benefit of CAR T cells in older patients.
    Blood. 2020;135:2020-2021.

  287. RATNER L
    Predicting the future: adult T-cell leukemia.
    Blood. 2020;135:2013-2014.

    May 2020
  288. ESKELUND CW, Husby S, Favero F, Klausen TW, et al
    Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
    Blood. 2020;135:2000-2004.

  289. DE BOER M, Hauptmann M, Hijmering NJ, van Noesel CJM, et al
    Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast.
    Blood. 2020 May 26. pii: 457298. doi: 10.1182/blood.2019004498.

  290. GAYDOSIK AM, Queen DS, Trager MH, Akilov OE, et al
    Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.
    Blood. 2020 May 21. pii: 456039. doi: 10.1182/blood.2019004725.
    PubMed     Abstract available

  291. MCGINNIS E, Farinha P
    Intravascular large B-cell lymphoma presenting with acute encephalopathy.
    Blood. 2020;135:1916.

  292. HESLOP HE
    Sensitizing Burkitt lymphoma to EBV-CTLs.
    Blood. 2020;135:1822-1823.

  293. YAHALOM J, Dabaja BS, Ricardi U, Ng A, et al
    ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic.
    Blood. 2020;135:1829-1832.
    PubMed     Abstract available

  294. DALTON T, Doubrovina E, Pankov D, Reynolds R, et al
    Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.
    Blood. 2020;135:1870-1881.
    PubMed     Abstract available

  295. RAMOS JC, Sparano JA, Chadburn A, Reid EG, et al
    Impact of Myc in HIV-associated Non-Hodgkin Lymphomas Treated with EPOCH, and Outcomes with Vorinostat (AMC075 Trial).
    Blood. 2020 May 19. pii: 456029. doi: 10.1182/blood.2019003959.
    PubMed     Abstract available

  296. JELINEK T, Zuchnicka J
    Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
    Blood. 2020;135:1816.

  297. MORIN RD, Scott DW
    DLBCL subclassification: divide and conquer?
    Blood. 2020;135:1722-1724.

  298. LACY SE, Barrans SL, Beer PA, Painter D, et al
    Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.
    Blood. 2020;135:1759-1771.
    PubMed     Abstract available

  299. GERBY B, Hoang T
    A targetable cue in T-cell malignancy.
    Blood. 2020;135:1616-1617.

    April 2020
  300. LIAPIS K, Paterakis G
    Circulating angioimmunoblastic T-cell lymphoma cells.
    Blood. 2020;135:1607.

  301. SWENSON S, Gilbreath T, Vahle HE, Hynes-Smith RW, et al
    E3 Ligase, UBR5, HECT domain mutations in lymphoma control maturation of B cells.
    Blood. 2020 Apr 23. pii: 454471. doi: 10.1182/blood.2019002102.
    PubMed     Abstract available

  302. Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019;134(18):1528-1532.
    Blood. 2020;135:1507.

    Go with the flow: simplified MRD in LMIC ALL.
    Blood. 2020;135:1414-1415.

  304. ZHANG W, Yang J, Zhou C, Hu B, et al
    Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.
    Blood. 2020 Apr 22. pii: 454449. doi: 10.1182/blood.2019002008.

  305. LO A, Campbell BA, Pickles T, Aquino-Parsons C, et al
    Long-Term Outcomes for Patients With Limited-Stage Follicular Lymphoma: Update of a Population-based Study.
    Blood. 2020 Apr 22. pii: 454451. doi: 10.1182/blood.2019004588.

  306. CHESON BD
    Predicting the future for DLBCL.
    Blood. 2020;135:1308-1309.

  307. MELANI C, Jaffe ES, Wilson WH
    Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.
    Blood. 2020;135:1344-1352.
    PubMed     Abstract available

  308. VERCELLINO L, Cottereau AS, Casasnovas O, Tilly H, et al
    High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
    Blood. 2020;135:1396-1405.
    PubMed     Abstract available

    Hotter is not more aggressive: baseline SUVmax in FL.
    Blood. 2020;135:1191-1192.

  310. ALDERUCCIO JP, Isrow D, Reis IM, Iyer SG, et al
    Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?
    Blood. 2020;135:1299-1302.

  311. KRISHNAMURTHY K, Sriganeshan V
    Extracavitary primary effusion lymphoma presenting as a thalamic mass in a patient with multicentric Castleman disease.
    Blood. 2020;135:1190.

  312. SIMKINS A, Dunleavy K
    Tackling Burkitt when it's back.
    Blood. 2020;135:1078-1080.

  313. FLOWERS C, Leonard JP, Fowler N
    Lenalidomide in follicular lymphoma.
    Blood. 2020 Apr 1. pii: 454206. doi: 10.1182/blood.2019001751.
    PubMed     Abstract available

    March 2020
  314. JANZ S
    MYC needs MNT to drive B cells over the edge.
    Blood. 2020;135:977-978.

  315. NGUYEN HV, Vandenberg CJ, Ng AP, Robati MR, et al
    Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Blood. 2020;135:1019-1031.
    PubMed     Abstract available

  316. RISUENO A, Hagner PR, Towfic F, Fontanillo C, et al
    Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
    Blood. 2020;135:1008-1018.
    PubMed     Abstract available

  317. CARPIO C, Bouabdallah R, Ysebaert L, Sancho JM, et al
    Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
    Blood. 2020;135:996-1007.
    PubMed     Abstract available

  318. CHIANG MY
    Tearing ATL apart to find HTLV's sinister plans.
    Blood. 2020;135:887-889.

  319. RUPPERT AS, Dixon JG, Salles GA, Wall A, et al
    International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI.
    Blood. 2020 Mar 13. pii: 452696. doi: 10.1182/blood.2019002729.
    PubMed     Abstract available

  320. SCHODER H, Polley MY, Knopp MV, Hall NC, et al
    Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.
    Blood. 2020 Mar 13. pii: 452697. doi: 10.1182/blood.2019003277.
    PubMed     Abstract available

    Sugar-coated BCR kept during FL clonal evolution.
    Blood. 2020;135:784-785.

  322. SROUR SA, Singh H, McCarty J, de Groot E, et al
    Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
    Blood. 2020;135:862-865.

  323. DIEHL LF
    The efficacy-toxicity conundrum: breaking the mold.
    Blood. 2020;135:704-706.

    February 2020
  324. DUFVA O, Koski J, Maliniemi P, Ianevski A, et al
    Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
    Blood. 2020;135:597-609.
    PubMed     Abstract available

  325. DE SMEDT R, Morscio J, Reunes L, Roels J, et al
    Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.
    Blood. 2020 Feb 13. pii: 452489. doi: 10.1182/blood.2019003880.
    PubMed     Abstract available

    January 2020
  326. LAURENT C, Nicolae A, Laurent C, Le Bras F, et al
    Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
    Blood. 2020;135:360-370.
    PubMed     Abstract available

  327. BASSET M, Defrancesco I, Milani P, Nuvolone M, et al
    Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.
    Blood. 2020;135:293-296.

  328. STAIGER AM, Hoster E, Jurinovic V, Winter S, et al
    Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.
    Blood. 2020;135:181-190.
    PubMed     Abstract available

    A role for NFAT signaling in ABC-DLBCL.
    Blood. 2020;135:81.

  330. XIU Y, Dong Q, Fu L, Bossler A, et al
    Coactivation of NF-kappaB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion.
    Blood. 2020;135:108-120.
    PubMed     Abstract available

  331. ALDOSS I, Forman SJ
    How I Treat: Selecting CD19 Targeted Immunotherapies in Adult Patients with Advanced Acute Lymphoblastic Leukemia.
    Blood. 2020 Jan 3. pii: 430058. doi: 10.1182/blood.2019002132.
    PubMed     Abstract available

    December 2019
  332. ZHU H, Blum R, Bjordahl R, Gaidarova S, et al
    Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity.
    Blood. 2019 Dec 19. pii: 429991. doi: 10.1182/blood.2019000621.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.